Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.84 HKD 4.07%
Market Cap: 2.6B HKD

Antengene Corporation Ltd
Pre-Tax Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Antengene Corporation Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Antengene Corporation Ltd
HKEX:6996
Pre-Tax Income
-ÂĄ581.2m
CAGR 3-Years
42%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ3.8B
CAGR 3-Years
7%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ3.7B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
24%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ5.9B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
13%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ5B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
5%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Pre-Tax Income
ÂĄ225.5m
CAGR 3-Years
-14%
CAGR 5-Years
-7%
CAGR 10-Years
N/A

Antengene Corporation Ltd
Glance View

Market Cap
2.6B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
1.79 HKD
Overvaluation 53%
Intrinsic Value
Price

See Also

What is Antengene Corporation Ltd's Pre-Tax Income?
Pre-Tax Income
-581.2m CNY

Based on the financial report for Dec 31, 2023, Antengene Corporation Ltd's Pre-Tax Income amounts to -581.2m CNY.

What is Antengene Corporation Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
-32%

Over the last year, the Pre-Tax Income growth was 3%. The average annual Pre-Tax Income growth rates for Antengene Corporation Ltd have been 42% over the past three years , -32% over the past five years .

Back to Top